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Recently, the presence of microsatellite instability (MSI) has been reported in gastric cancer and associated with older
age of presentation, distal tumor location, early disease staging, and better overall prognosis. Different characteristics in
presentation and in tumor behavior may be explained by different genetic alterations during carcinogenesis of gastric
cancer. Identification of specific genetic pathways in gastric cancer may have direct impact on prognosis and selection of
treatment strategies.
PATIENTS AND METHODS: All 24 patients were treated by radical surgery. Fragments of normal and tumor tissues
were extracted from the specimen and stored at -80oC before DNA purification and extraction. PCR amplification utilizing
microsatellite markers was performed. Tumors presenting PCR products of abnormal sizes were considered positive for
microsatellite instability (MSI+).
RESULTS: Five patients (21%) had tumors that were MSI+ in at least 1 marker. In the group of patients with Lauren’s
intestinal-type gastric carcinoma, 3 had tumors that were MSI+ (23%), while in the group of diffuse-type gastric cancer, 2
patients had tumors that were MSI+ (19%). The mean age of presentation and the male:female ratio was similar in both
groups. Tumors that were MSI+ were more frequently located in proximal portion of the stomach compared to microsatellite-
stable (MSS) tumors (40% vs. 16%). Although there was a trend of patients with MSI+ tumors towards a proximal gastric
tumor location, early staging, and negative lymph node metastasis, there was no statistical significance compared to those
with MSS tumors (P >.1). Comparison of overall and disease-free survival between gastric tumors that were MSI+ and those
that were MSS found no statistically significant differences (P >.1).
CONCLUSIONS: Microsatellite instability is a frequent event in gastric carcinogenesis and shows a trend towards
distinct clinical and pathological characteristics of gastric cancer.
KEY WORDS: Gastric cancer. Genetics. Microsatellite instability.
Gastric adenocarcinoma is one of
the most common malignancies world-
wide, but genetic steps involved in its
carcinogenesis remain uncertain. Mul-
tiple genetic alterations affecting
proto-oncogenes, tumor suppressor
genes, and mismatch repair genes
(MMR) appear to be associated with
the development of various human
cancers including colorectal and gas-
tric cancers.
Identification of MMR genes,
which are responsible for hereditary
nonpolyposis colon cancer, led to the
hypothesis of a distinct genetic path-
way in colorectal cancer associated
with microsatellite instability (MSI) or
replication error phenotype (RER) by
alterations in 1 or more of these genes,
more frequently in Msh2 and Mlh1.17,7
Recently, the presence of MSI has
also been reported in gastric cancer
along with the association of these al-
terations with older age of presenta-
tion, distal tumor location, early dis-
ease staging, and better overall prog-
nosis.5,10,13 Different characteristics in
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presentation and in tumor behavior
may be explained by different genetic
alterations during carcinogenesis of
gastric cancer. Identification of specific
genetic pathways in gastric cancer
may have direct impact on prognosis
and selection of treatment strategies.
We report in this prospective study
involving 24 Brazilian patients with
solitary and sporadic gastric cancer, the
incidence of MSI, its correlation with
epidemiological, clinical and patho-
logical characteristics, and impact on
overall and disease-free survival.
PATIENTS AND METHODS
Twenty-four patients with a
preoperative diagnosis of gastric ad-
enocarcinoma treated at Hospital das
Clínicas, Faculty of Medicine, Univer-
sity of São Paulo (Department of Gas-
troenterology) and “Hospital Alemão
Osvaldo Cruz” entered the study. All
patients were treated by radical surgery
including gastric resection with free
margins and D2 lymphadenectomy ac-
cording to the JSRGC anatomical clas-
sification. All patients were eligible for
the study and had their resected speci-
mens available for pathologic exami-
nation and MSI determination.
Tumors were characterized accord-
ing to Lauren´s histologic classifica-
tion into intestinal - and diffuse-type
gastric cancer and staged according to
JGCA recomendations.19 The same sur-
geon and surgical team performed all
operations.
Of the 24 patients, 15 were male
(62.5%) and 9 female (37.5%). The mean
age was 63.6 years (range, 26 to 86
years). Eleven patients (46%) had
Lauren’s intestinal-type adenocarcinoma
while 13 patients (54%) had diffuse-type
adenocarcinoma. Twelve patients (50%)
had tumors located in lower third of the
stomach, 7 in the middle third (29%), and
5 in the upper third (21%). Total gast-
rectomy was performed in 11 patients
(46%), and subtotal gastrectomy in the
remaining 13 patients (54%). Associated
resection of the spleen was performed in
8 patients who were treated by total gas-
trectomy (84.5%). Pathological exami-
nation revealed a mean number of lymph
nodes resected of 33.6 (range, 17 to 76).
Patient demographics are summarized in
Table 1.
Nine patients (37.5%) had T1 (mu-
cosa and submucosa) tumors, 2 pa-
tients (8.3%) had T2 (muscular layer),
12 patients (50%) had T3 (serosal or
subserosal), and 1 (4.2%) had a T4
(adjacent organs). Nine patients
(37.5%) had no positive lymph nodes
(N0), 9 (37.5%) were classified as N1,
and 6 (25%) were classified as N2.
All patients had preoperative en-
doscopic biopsies of primary tumors.
However, these preoperative studies
did not include normal adjacent tissue
biopsies for Helicobacter pylori infec-
tion determination. Since the surfaces
of all resected specimens were washed
with saline solution in order to avoid
DNA contamination, determination of
Helicobacter pylori infection would
be seriously compromised and inaccu-
rate in this setting. For this reason,
pathologic examination of the resected
specimen did not include H. pylori in-
fection determination.
Only 1 patient (4.2%) had a distant
metastasis in the left ovary and was
classified as stage IV. Eight patients
(33.3%) had stage I disease (stage Ia +
Ib), 5 (21%) had stage II, and 10
(41.5%) had stage III (IIIa + IIIb) dis-
ease. Stage classification and patient
distribution are summarized in Tables
2 and 3.
Table 1 - Patient Demographics (N=24).
Age 26-86
Mean 63.6 years
Gender
Male 15 (62.5%)
Female 9 (37.5%)
Histologic type (Lauren)
Intestinal 13 (54%)
Diffuse 11 (46%)
Tumor location
L (distal third) 12 (50%)
M (intermediate) 7 (29%)
U (proximal third) 5 (21%)
Types of gastrectomy
Total 11 (46%)
Subtotal 13 (54%)
Lymphadenectomy (17-76)
Mean 34 lymph nodes
Table 2 - Stage and histologic type (Lauren´s classification) (N=24).
(JGCA-1998) Intestinal Diffuse Total
Ia 5 (38.5%) 1 ( 9%) 6 (25%)
Ib 0 2 (18%) 2 ( 8%)
II 4 (30%) 1 ( 9%) 5 (21%)
IIIa 1 ( 8%) 6 (55%) 7 (29%)
IIIb 2 (15.5%) 1 ( 9%) 3 (13%)
IV 1 ( 8%) 0 1 ( 4%)
(TNM) Intestinal Diffuse Total
T
T1 5 (38.5%) 4 (36%) 9 (37.5%)
T2 1 ( 8%) 1 ( 9.5%) 2 ( 8%)
T3 7 (54%) 5 (45%) 12 (50%)
T4 0 1 ( 9.5%) 1 ( 4%)
N
N0 8 (61.5%) 1 ( 9%) 9 (37.5%)
N1 2 (15.5%) 7 (63%) 9 (37.5%)
N2 3 (23%) 3 (27%) 6 (25%)
M
M0 12 (91%) 11 (100%) 23 (96%)
M1 1 ( 9%) 0 (0%) 1 ( 4%)
             Total 13 (100%) 11 (100%) 24 (100%)
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Tissue and DNA preparation
Fragments of normal and tumor
tissues were extracted from the speci-
men immediately after resection. The
specimen surface was washed with sa-
line fluid prior to fragment extraction
to avoid DNA contamination of tissues
sent for MSI determination. Areas of
tissue extraction from the specimen
were demarcated for routine pathologic
examination. Only tissue fragments
containing adenocarcinoma were in-
cluded for MSI analysis. Normal areas
were used as controls. Tissues were
stored at -80oC before DNA purifica-
tion and extraction.
Tissues were incubated overnight
at 550C in a buffer containing 100 mM
TRIS-HCl (pH 8.5), 5 mM EDTA, 200
µg of proteinase K/mL, and 0.2% so-
dium dodecyl sulfate. The samples
were cooled to room temperature, and
DNA was precipitated with isopropa-
nol and dissolved in 500 mL of buffer
containing 10 mM TRIS (pH 8.2) and
1 mM EDTA.1
Microsatellite markers and PCR am-
plification
Oligonucleotide primers for
microsatellite markers from the long
arm of chromosome 18 were designed
on the basis of published sequences
(D18S55, D18S58, D18S61, D18S64,
and D18S69)8. PCR-based dinucleotide
repeat assays were carried out in 96-well
plates for 30 cycles; each cycle was car-
ried out at 950C for 30 seconds, 500C
for 1 minute, and 700C for 1 minute.
Two volumes of stop buffer (95% of
formamide, 20 uM sodium hydroxide,
and 0.05% bromophenol blue and xy-
lene cyanate) were added at the end of
the amplification, plates were boiled in
a water bath for 10 minutes at 1000C,
and the samples were loaded onto 7%
polyacrylamide gels containing 32%
formamide and 5.6 M urea.4
Determination of microsatellite in-
stability (MSI)
Tumors presenting PCR products of
abnormal sizes were considered posi-
tive for MSI (MSI+). Tumors that were
MSI+ for 1 marker were considered
low-MSI, and tumors that were MSI+
for 2 or more markers were considered
high-MSI. Detection of PCR products
was made by Sybr-Green staining of
the polyacrylamide gels.
Statistical analysis
Statistical analysis was performed
using the Student t test and chi-square
test. Overall survival and disease-free
Kaplan-Meier curves were compared
using the log-rank test.
RESULTS
Five patients (21%) had tumors that
were MSI+ in at least 1 marker (MSI+
group), and 19 patients (79%) had
tumors that were microsatellite-stable
(MSS) (MSS group). Of the patients
having tumors that were MSI+ 3
(12.5%) were considered high-MSI, and
2 (8.3%) were considered low-MSI.
In the group of patients with
Lauren’s intestinal-type gastric carci-
noma, 3 (23%) had tumors that were
MSI+, while in the group of diffuse-
type gastric cancer, 2 patients (19%)
were MSI+. These differences were not
statistically significant (P = .58).
In the MSI+ group, the mean age
was 63.6 years and the male:female ra-
tio was 1.5; in the MSS group, the mean
age was also 63.6 and the male:female
ratio was 1.75. Tumor location in pa-
tients having MSI+ tumors was 1 (20%)
in the distal third, 2 (40%) in the mid-
dle third, and 2 (40%) in the upper
third of the stomach. In the MSS group,
11 patients (58%) had tumors in the
lower third, 5 (26%) in the middle, and
3 (16%) in the upper third of the stom-
ach. Three patients in the MSI+ group
(60%) and 5 patients in the MSS group
(26%) had Stage I disease. Lymph node
metastasis was present in 1 patient in
the MSI+ group (20%) and in 14 pa-
tients in the MSS group (74%). There
were no statistically significant differ-
ences between groups in terms of age
and gender distribution (P = .9 and P =
.6, respectively). Although there was a
trend for patients in MSI+ group to-
wards proximal tumor location, early
staging, and negative lymph node me-
tastasis, there was no statistical signifi-
cance, P >.1. (Table 4)
In the group of patients with
Lauren’s intestinal-type gastric carci-
noma, the mean overall survival was
33.6 months for patients with MSI+
tumors and 33.1 months for patients
with MSS tumors. In this subgroup,
none of the patients with MSI+ tumors
had recurrence of the disease, while 2
patients with MSS tumors (20%) had
systemic recurrent disease. In this group
of patients, when patients with MSI+
and MSS tumors are compared within
stages, mean overall survival and dis-
ease recurrence rates are identical.
In the group of patients with
Lauren’s diffuse-type gastric carci-
noma, mean overall survival was 45.5
months for patients with tumors that
were MSI+ and 30.9 months for pa-
Table 3 - Japanese Gastric Cancer
Association Staging System-199819.
Staging JGCA (1998)
Stage T N M
IA T1 N0 M0
IB T1 N1 M0
T2 N0 M0
II T1 N2 M0
T2 N1 M0
T3 N0 M0
IIIA T2 N2 M0
T3 N1 M0
T4 N0 M0
IIIB T3 N2 M0
T4 N1 M0
IV T4 N2 M0
Any T N3 Any M
Any T Any N M1
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tients with tumors that were MSS. In
this subgroup, none of the patients
with MSI+ tumors had recurrence of
the disease, while 3 patients with MSS
tumors (20%) had systemic recurrent
disease. These differences were not sta-
tistically significant. In patients with
Lauren´s diffuse-type gastric cancer,
the difference between mean overall
survival and disease-free survival was
seen only in the stage III subgroup of
patients, where the mean survival time
of patients with MSI+ tumors was 54
months with no recurrence and for pa-
tients with MSS tumors was 31.5
months with 1 recurrence (25%). (Figs.
1 and 2). However, the small number
of patients in this subgroup (stage III)
may account for such differences.
DISCUSSION
We found microsatellite instability
(MSI) in 21% of 24 sporadic and soli-
tary gastric adenocarcinomas in Brazil-
ian patients, which is in accordance
with other reports in the literature,
which cite incidences of 9% to
33%.10,13,8,16,2,18,6 Furthermore, we also
found similar results concerning the
frequent early disease staging encoun-
tered by others, since 60% of MSI+
tumors were stage I (Ia + Ib), while
only 26% of the MSS tumors were
stage I. Other characteristics have been
associated with MSI+ gastric tumors,
such as advanced age of patients,
distally located tumors, and better
overall prognosis.13.16,2,18,6 The associa-
tion with these latter characteristics
was not observed in this study. Al-
though not statistically significant,
MSI+ tumors in our study were more
frequently located in the proximal
third (40%) of the stomach when com-
pared to MSS tumors (16%). Also,
mean age was identical between both
groups at 63.6 years.
We compared overall and disease-
free survival between patients with
MSI+ and MSS gastric tumors and
found no statistically significant dif-
ferences. These results also differ from
earlier reports in the literature.13,16,2,18,6
The presence of the replication er-
ror (RER) phenotype in gastric cancer
appears to represent an independent
genetic pathway in gastric carcinogen-
esis.9,12,15 The incidence of this pheno-
type has been reported to be even
higher (50%) in multiple or synchronic
gastric tumors.9 A recent study has
shown that tumors that exhibit RER
rarely exhibit loss of heterozygosity,
considered to be the other major ge-
netic pathway in gastric carcinogen-
esis.12,11 Additionally, multiple tumors
in the same stomach usually present
the same phenotype more frequently
with MSI.12 These synchronic or mul-
tiple gastric tumors may be further di-
vided in 2 subgroups, the first when
there is an adenoma-associated adeno-
carcinoma (type I) and the second
when there is no adenoma associated
(type II). These authors report an im-
Table 4 - Clinicopathological differences between microsatellite instability (MSI+)
and microsatellite-stable (MSS).
MSI+ MSS P
N 05  19
Age (mean) 63.3 63.6 .9
Gender (M:F)  1.5 1.75 .6
Tumor location
L 1 (20%) 11 (58%) .24
M 2 (40%)  5 (26%)
U 2 (40%)  3 (16%)
Operation (type of gastrectomy)
Total 3 (60%)  8 (42%) .76
Subtotal 2 (40%) 11 (58%)
Histologic type (Lauren)
Intestinal 3 (60%) 10 (52%) .58
Diffuse 2 (40%)  9 (48%)
Stage
Early (stage I) 3 (60%)  5 (26%) .48
Advanced (II-IV) 2 (40%) 14 (74%)
Lymph node status
N negative 4 (80%) 5 (26%) .54
Figure 1 - Overall survival of patients with gastric cancer according to microsatellite instability
(MSI) status.
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portant difference in the incidence of
MSI between these subgroups, being
more frequent in type I (56%) and in-
frequent in type II (8%).9 The presence
of MSI may be associated with muta-
tions in specific target genes such as
TGFb RII, IGFII R, and BAX. 13,9 The
combination of mutation in target
genes may be responsible for differ-
ences in biological behavior and clini-
cal-pathological characteristics within
MSI+ tumors.
Association of genetic alterations
and dietary factors have also been
studied. Recently, an Italian study has
suggested a correlation between red
meat ingestion and MSI+ gastric can-
cer, suggesting an environmental fac-
tor as a causative event in susceptible
individuals or increased tolerance to
DNA damage associated with reduced
MMR activity.14
MLH1 and MSH2 appear to be re-
sponsible for the majority of the MSI
both in colorectal cancer and gastric
cancer.3,4 The mechanism involved
more frequently is hypermethylation of
the MLH1 promoter region resulting in
underexpression of the protein as ob-
served by immunohistochemistry.3,4,1
Recent observations have indicated
that even adjacent noncancerous tis-
sue may present hypermethylation of
MLH1 promoter region and may be as-
sociated with increased risk for the de-
velopment of gastric cancer.15,1
These results suggest that MSI may
be an important and early event in a
subset of gastric adenocarcinomas. In
our study, although not statistically
significant, MSI+ tumors showed a
trend towards early disease staging,
proximal gastric location, and lower
risk for lymph node metastasis. Fur-
thermore, we found no difference in
the mean age of these patients, over-
all survival, and disease-free survival,
in contrast with observations of oth-
ers.13,16,2,18,6 We believe that tumor ag-
gressiveness and biological behavior
may be determined by target gene mu-
tations and thus these should be iden-
tified in order to compare different
subsets of gastric tumors all exhibiting
the RER or MSI+ phenotype. Further-
more, MSI+ gastric cancer may be the
end-result of environmental or dietary
factors in a susceptible stomach. These
two arguments may account for the
clinical-pathologic and survival differ-
ences observed in our study.
Identification of genetic pathways
in gastric cancer may be of great im-
portance and have direct practical im-
plications in the management of gas-
tric cancer. Tumor biological behavior
may be directly associated with spe-
cific genetic alterations during car-
cinogenesis of gastric cancer. These
differences may account for the hetero-
geneity of presentation and prognosis
of this neoplasm. Thus, patients may
have a distinct prognosis, presentation
characteristics, and response to
therapy according to specific genetic
alterations and pathway.
Treatment of gastric cancer is
based on radical surgical resection.
Extent of gastric resection is deter-
mined by tumor histology and loca-
tion. Some genetic alterations, such as
MSI and mutations in MMR genes,
may be associated with increased risk
of multiple synchronous tumors and
therefore may require total gastrec-
tomy as an initial treatment strategy,
once it can be diagnosed
preoperatively. An environmental fac-
tor may also influence these aspects,
since dietary factors and specific car-
cinogenic agents may influence in a
variable manner the manifestation in
a common genetic background. Our
results differ from other reports in sev-
eral aspects of tumor presentation and
behavior of MSI+ gastric tumors,
which may be partially explained by
a different environmental factor not
yet identified.
Hereditary genetic alterations may
be responsible for increased suscepti-
bility for cancer. Detection of these ge-
netic changes may allow identification
of relatives of patients with gastric can-
cer with increased risk for develop-
ment of the disease, such as hereditary
diffuse and intestinal gastric cancer.
Distinct screening programs for these
families may lead to higher rates of
Figure 2 - Disease-free survival according to microsatellite instability (MSI) status.
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early gastric cancer diagnosis, improve
overall survival, and revive the discus-
sion about prophylactic treatment of
gastric cancer.
Adjuvant therapy has not yet
shown consistent improvement in
overall survival for gastric cancer.
Characterization of specific genetic al-
terations and pathways may allow
identification of a subset of patients
with gastric cancer that is susceptible
to specific antineoplastic drugs. Fur-
thermore, neoadjuvant treatment with
chemotherapy and radiotherapy may
prove to be beneficial in selected cases
of advanced or even unresectable dis-
ease. Alterations in specific genes such
as p53 and other genes associated with
apoptosis may be responsible for some
of these differences observed in
adjuvant treatment responses. In
theory, a genetic pathway that does not
include frequent alterations in such
genes may be associated with better
response to chemotherapy and radio-
therapy with adjuvant or neoadjuvant
intent. As mentioned earlier, MSI may
represent a distinct genetic pathway of
gastric cancer and does not include
frequent alterations in p53 gene and
others. One could expect better re-
sponse rates with specific chemothera-
peutic regimens for adjuvant treatment
in MSI+ tumors.
Finally, identification of these spe-
cific genetic alterations and pathways
may aid in the development of new
drugs involving gene therapy, such as
viral vectors directed to specific target
genes causing tumor cell death with
minimum toxicity.
The importance of the study of ge-
netic alterations in gastric cancer devel-
opment cannot be overemphasized, but
new management strategies based on
these characteristics should await fur-
ther consistent results. Caution should
be taken with interpretation of these re-
sults with special consideration to dif-
ferent geographical areas and other en-
vironmental factors. These factors may
be responsible for different influences
in gastric carcinogenesis, giving rise to
tumors with distinct biological
behaviors and presentation over simi-
lar genetic alterations or pathways.
In conclusion, MSI is a frequent
event in gastric carcinogenesis and
can be easily detected. The presence
of MSI may be associated with distinct
clinical, epidemiological, and patho-
logical characteristics, such as primary
tumor location, disease stage, and pres-
ence of lymph node metastases. Differ-
ent geographical areas and environ-
mental factors may further influence
the association between MSI and these
features in gastric cancer. Identifica-
tion of genetic and molecular events
in gastric carcinogenesis may result in
improvement of disease management
and overall survival.
RESUMO
Perez RO e col. Instabilidade de
microsatelites no cancer gástrico
solitário e esporádico. Rev. Hosp.
Clín. Fac. Med. S. Paulo 59(5):
279-285, 2004.
A presença de Instabilidade de
microsatellites (IMS) tem sido relata-
da no cancer gastrico e associada a pa-
cientes com idade mais avançada, lo-
calização mais distal do tumor,
estadios mais precoces e melhor prog-
nostico. Relatamos neste prospectivo
estudo envolvendo 24 pacientes com
cancer gastrico solitario e esporadico,
a incidencia de IMS, sua correlação
com parametros epidemiologicos,
clinicos e anatomo patológicos e o seu
impacto sobre a sobrevida geral e li-
vre de doença.
PACIENTES E MÉTODOS: To-
dos os pacientes haviam sido tratados
com cirurgia radical. Fragmentos de
tecido normal e tumoral eram
extraidos das peças e armazenados a –
80oC antes da extração e purificação
DNA. Realizava-se então a amplifica-
ção com PCR utilizando marcadores
específicos de microsatelites. Os tumo-
res que apresentavam produtos de am-
plificação anormais foram considera-
dos positivos para IMS.
RESULTADOS: Cinco pacientes
(21%) apresentaram Instabilidade de
microsatelites (IMS+) com pelo menos
um marcador (primer) No grupo de pa-
cientes com adenocarcinomas gástri-
cos do tipo histológico de Lauren, três
apresentavam IMS (23%) enquanto no
grupo portador de cancar gástrico
difuso, dois pacientes mostraram IMS
(19%).. Embora haja uma tendência
dos pacientes IMS+ apresentarem tu-
mores de localização mais proximal,
estadios mais precoces e ausência de
metástases linfonodais, não se obser-
vou diferenças estatisticamente signi-
ficativas (p > 0,1). A comparação en-
tre as taxas de sobrevida geral e livre
de doença não mostrou significância
estatistica (p > 0,1).
CONCLUSÕES: IMS é um even-
to frequente na carcinogese gástrica e
pode estar associado a caracteristicas
clinicas e anátomo-patológicas do cân-
cer gástrico.
UNITERMOS: Câncer gástrico.
Genética. Instabilidade de
microsatelites.
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